Related Experiment Video
Updated: Apr 23, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Silymarin induces cell cycle arrest and apoptosis in ovarian cancer cells
1Department of Obstetrics and Gynecology, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, Hubei Province, China.
Abstract:
The polyphenolic flavonoid silymarin that is the milk thistle extract has been found to possess an anti-cancer effect against various human epithelial cancers. In this study, to explore the regulative effect of silymarin on human ovarian cancer line A2780s and PA-1 cells, 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide assay and flow cytometry were respectively used to determine the inhibitory effect of silymarin on the both cell lines, and to measure their cell cycle progression. Apoptosis induction and mitochondrial membrane potential damage were separately detected by terminal deoxynucleotidyl transferase-mediated 2'-deoxyuridine 5'-triphosphate nick end labeling assay and 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide staining. Additionally, western blotting was applied to determine cytochrome C release and expression levels of p53, p21, p27, p16, CDK2, Bax, Bcl-2, procaspase-9, procaspase-3, cleaved caspase-9 and caspase-3 proteins. The activity of caspase-9 and caspase-3 was measured using Caspase-Glo-9 and Caspase-Glo-3 assay. The results indicated that silymarin effectively suppressed cell growth in a dose- and time-dependent manner, and arrested cell cycle progression at G1/S phase in A2780s and PA-1 cells via up-regulation of p53, p21, and p27 protein expression, and down-regulation of CDK2 protein expression. Additionally, silymarin treatment for 24h at 50 and 100µg/ml resulted in a reduction of mitochondrial membrane potential and cytochrome C release, and significantly induced apoptosis in A2780s and PA-1 cells by increasing Bax and decreasing Bcl-2 protein expression, and activation of caspase-9 and caspase-3. Therefore, silymarin is a possible potential candidate for the prevention and treatment of ovarian cancer.
Insights
Silymarin, a milk thistle extract, effectively inhibits ovarian cancer cell growth by halting cell cycle progression and inducing apoptosis. This natural compound shows potential for ovarian cancer prevention and treatment.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Silymarin, a flavonoid from milk thistle, exhibits anti-cancer properties against various epithelial cancers.
- Ovarian cancer remains a significant health concern with a need for novel therapeutic strategies.
Purpose of the Study:
- To investigate the anti-cancer effects of silymarin on human ovarian cancer cell lines (A2780s and PA-1).
- To elucidate the mechanisms underlying silymarin's action, including cell cycle regulation and apoptosis induction.
Main Methods:
- Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
- Cell cycle progression, apoptosis, and mitochondrial membrane potential were analyzed via flow cytometry and specific staining assays.
- Protein expression levels (p53, p21, p27, CDK2, Bax, Bcl-2, caspases) and enzyme activities were determined using Western blotting and Caspase-Glo assays.
Main Results:
- Silymarin suppressed ovarian cancer cell growth in a dose- and time-dependent manner.
- Silymarin induced G1/S phase cell cycle arrest by modulating p53, p21, p27, and CDK2 expression.
- Silymarin triggered apoptosis through mitochondrial pathway activation, evidenced by decreased mitochondrial membrane potential, cytochrome C release, altered Bax/Bcl-2 ratio, and caspase-9/-3 activation.
Conclusions:
- Silymarin demonstrates significant anti-cancer activity against human ovarian cancer cells.
- Silymarin's mechanisms involve cell cycle arrest and apoptosis induction, suggesting its potential as a therapeutic agent for ovarian cancer.
Related Concept Videos
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...
MicroRNAs

